Recce Pharmaceuticals - R327 progressing in rapid infusion study
Recce recently reported the completion of its data review from its earlier long-infusion Phase I study of the intravenous (IV) RECCE 327 (R327)...
311 Views
Recce Pharmaceuticals - Gearing up for more R327 studies
Recent months have been eventful for Recce Pharmaceuticals, with the company presenting its Q323 operational update and announcing ethics approval...
163 Views
Recce Pharmaceuticals - Seeking a breakthrough in sepsis
Recce Pharmaceuticals is developing a novel class of broad-spectrum synthetic anti-infective drugs to which, so far, all tested bacteria have been...
242 Views